Risk Stratification of Orbital Tumors Based on MRl and Artificial Intelligence

March 28, 2024 updated by: Beijing Tongren Hospital
Orbital tumors can be categorized into benign and malignant tumors, and there are significant variations in their biological behavior, treatment, and prognosis. This study aims to enhance the accurate diagnosis and risk stratification of orbital tumors using artificial intelligence (AI) technology and multiparameter magnetic resonance imaging (MRI) data. It further explores the intrinsic relationship between MRI and the differential diagnosis of benign and malignant orbital tumors, as well as the pathological subtypes of malignant tumors and Ki-67 expression levels. This research aims to aid in guiding personalized diagnosis and treatment decision-making for patients with orbital tumors while promoting the practical application and incorporation of AI technology.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Although orbital tumors are less common than other eye-related diseases, they can be extremely detrimental to patients. Not only can they cause physical disfigurement, but they can also lead to functional impairments such as diminished vision and restricted eye movement. Orbital tumors can be categorized as either benign or malignant, and there are significant disparities in their biological behavior, treatment approaches, outcomes, and prognosis, which complicates the processes of differential diagnosis and treatment selection. For malignant lesions, the treatment plans and prognosis of patients vary due to the different pathological types and stages. Hence, there is a pressing clinical necessity to devise accurate diagnostic methods for orbital tumors. Multiparametric magnetic resonance imaging (mp-MRI) currently stands as the leading non-invasive imaging technique for diagnosing orbital tumors. This study is centered on precise diagnosis of orbital tumor risk stratification, utilizing artificial intelligence algorithm technology to explore the inherent connection between MRI images and the distinguishing diagnosis of benign and malignant orbital tumors, histological types and Ki-67 expression levels of malignant tumors. It aims to integrate clinical information and quantitative MRI features to construct prediction models, aid in guiding individual diagnosis and treatment decisions for patients with orbital tumors and facilitate the application and advancement of artificial intelligence technology. Specifically, the research objectives are outlined as follows:

  1. Establishing a deep learning-based automatic segmentation model for orbital tumors using a multi-sequence MRI dataset from multiple centers, thereby reducing the time required for manual delineation and proving beneficial for subsequent analysis.
  2. Developing a model for identifying malignant and benign orbital tumors using multiple machine learning algorithms combined with multi-sequence MRI dataset, with the aim of providing more precise information for distinguishing between these two entities.
  3. Constructing robust diagnostic models using machine learning or deep learning approaches with quantitative multi-sequence MRI features to identify the histological type and Ki-67 expression levels of malignant orbital tumors, with the purpose of enhancing detection rates and accuracy, thereby achieving risk stratification for patients with malignant orbital tumors.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
600

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with malignant or benign orbital tumors confirmed by pathology, who underwent multiparametric MRl (mp-MRl) at BeiiingTongren Hospital from 2015 to 2022, were included in this research. Otherwise, patients lacking a definitive pathological diagnosis or pre-operative multiparametric MRl (mp-MRl) were excluded from this investigation.

Description

Inclusion Criteria:

  • The patients with orbital tumors who underwent pre-operative multiparametricMRl (mp-MRl) at Beijing Tongren Hospital from 2015 to 2022.

Exclusion Criteria:

  • The patients without pre-operative multiparametric MRl (mp-MRl) or clear pathological diagnosis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Malignant orbital tumors
Patients with malignant orbital tumors (lymphoma, melanoma, ...) diagnosed by pathological confirmation.
Other: Multi-parametric MRI and image analysis by deep learning or machine learning algorithms
Diagnosis models are established using quantitative features extracted from the multi-parametric MRI images and further processed by appropriate deep learning or machine learning algorithms.
Benign orbital tumors
Patients with benign orbital tumors (cavernous hemangioma, inflammatory pseudotumor, ...) diagnosed by pathological confirmation.
Other: Multi-parametric MRI and image analysis by deep learning or machine learning algorithms
Diagnosis models are established using quantitative features extracted from the multi-parametric MRI images and further processed by appropriate deep learning or machine learning algorithms.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
The area under the curve of Receiver Operating Characteristic of the diagnostic models for the differential diagnosis of malignant and benign orbital tumors, high and low grades of histological types, and levels of Ki-67 expression in malignant ones.
Time Frame: Pre-operation
The area under the ROC curve is calculated by integrating the ROC curve, which plots Sensitivity against 1 - Specificity.
Pre-operation

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
The area under the Precision-Recall curve of the diagnostic models for the differential diagnosis of malignant and benign orbital tumors, high and low grades of histological types, and high and low levels of Ki-67 expression in malignant orbital tumors.
Time Frame: Pre-operation
The area under the precision-recall curve is determined by integrating the Precision-Recall curve, which plots Precision against Recall.
Pre-operation
Sensitivity of the diagnostic models for the differential diagnosis of malignant and benign orbital tumors, high and low grades of histological types, and high and low levels of Ki-67 expression in malignant orbital tumors.
Time Frame: Pre-operation
Sensitivity is calculated as the ratio of true positives to the sum of true positives and false negatives.
Pre-operation
Specificity of the diagnostic models for the differential diagnosis of malignant and benign orbital tumors, high and low grades of histological types, and high and low levels of Ki-67 expression in malignant orbital tumors.
Time Frame: Pre-operation
Specificity is calculated as the ratio of true negatives to the sum of true negatives and false positives.
Pre-operation
Accuracy of the diagnostic models for the differential diagnosis of malignant and benign orbital tumors, high and low grades of histological types, and high and low levels of Ki-67 expression in malignant orbital tumors.
Time Frame: Pre-operation
Accuracy is calculated as the ratio of the sum of true positives and true negatives to the total number of cases.
Pre-operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Beijing Tongren Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Junfang Xian, M.D., Ph.D., Department of Radiology, Beijing Tongren Hospital, Capital Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2012

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 31, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 22, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 22, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 28, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 29, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 28, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • TREC2023-KY107

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Orbital Neoplasms

Clinical Trials on Multi-parametric MRI and image analysis by deep learning or machine learning algorithms

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings